Evaluation of CD68+ macrophages in relation to kidney outcomes in immunoglobulin light-chain amyloidosis
Kidney International · 2026
DOI: 10.1016/j.kint.2026.06.036 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney International, 2026. Verfasst von Muhammad Umaid Rauf und 26 weiteren Autor:innen. Beteiligte Einrichtung: National Amyloidosis Centre, University College London (Royal Free Campus), London, UK. Hauptthemen laut MEDLINE: Macrophages, Antigens, Differentiation, Myelomonocytic, Kidney, Antigens, CD. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
INTRODUCTION: The clinical course of systemic amyloidosis reflects the equilibrium between amyloid deposition and clearance, which varies across disease contexts. The mechanisms underlying amyloid clearance in vivo remain unclear, though experimental data implicate macrophage-mediated phagocytosis. Here we evaluated the impact of CD68+ macrophage infiltration in diagnostic kidney biopsies on kidney outcomes in immunoglobulin light-chain amyloidosis (AL) and examined the prognostic value of amyloid regression among patients with deep hematological response following chemotherapy. METHODS: Kidney biopsies from 708 consecutive patients with kidney AL treated at the UK National Amyloidosis Centre between 2000-2022 and achieved a deep and sustained hematologic response to chemotherapy were retrospectively stained with anti-CD68 antibody. Macrophage infiltration was scored on a scale of 0-3, and the relationship between macrophage score, interstitial fibrosis and tubular atrophy (IFTA), and kidney survival was evaluated. Among 396 patients in the cohort who had serial serum amyloid P component (SAP) scans at diagnosis and at two years of follow-up, the relationship between change in amyloid burden and long-term kidney outcomes was characterized. RESULTS: At five years, cumulative incidence of renal replacement therapy (RRT) was 14%, 22%, 40%, and 52% across macrophage scores 0, 1, 2, and 3, respectively. On multivariable Cox regression analysis, each one-point macrophage score increases independently and significantly predicted higher risk of RRT (hazard ratio 1.31, 95% confidence interval 1.09-1.56) alongside baseline estimated glomerular filtration rate, proteinuria, and IFTA. In a two-year landmark analysis, amyloid accumulation by SAP scintigraphy conferred a significant nine-fold increased risk of RRT versus amyloid regression (9.44, 3.25-27.39). Hematologic complete response was strongly associated with amyloid regression and prolonged renal survival. CONCLUSIONS: In AL amyloidosis, kidney CD68+ macrophage infiltration at diagnosis is independently associated with risk of progression to RRT even among patients with deep hematologic response. Regression of amyloid is associated with prolonged kidney survival. These findings highlight kidney CD68+ macrophage infiltration and subsequent SAP-defined amyloid regression as complementary predictors of kidney outcome in AL amyloidosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Amyloidosis Centre, University College London (Royal Free Campus), London, UK.
- Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Biostatistics Unit, University College London (UCL) Eastman Dental Institute, London, UK.
- National Amyloidosis Centre, University College London (Royal Free Campus), London, UK; Centre for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontin…
- National Amyloidosis Centre, University College London (Royal Free Campus), London, UK. Electronic address: j.gillmore@ucl.ac.uk.
Zitieren
APA
Rauf, M. U., Riefolo, M., Wong, E., Gilbertson, J., Petrie, A., Law, S., Razvi, Y., Mansell, J., Sheikh, A., Carruthers, J., Ioannou, A., Porcari, A., Hutt, D., Rowczenio, D., Wurie, H., Ravichandran, S., Cohen, O. C., Khawaja, J., Bomsztyk, J., …, & Gillmore, J. D. (2026). Evaluation of CD68+ macrophages in relation to kidney outcomes in immunoglobulin light-chain amyloidosis. Kidney International. https://doi.org/10.1016/j.kint.2026.06.036
Vancouver
Rauf MU, Riefolo M, Wong E, Gilbertson J, Petrie A, Law S, et al. Evaluation of CD68+ macrophages in relation to kidney outcomes in immunoglobulin light-chain amyloidosis. Kidney International. 2026. doi:10.1016/j.kint.2026.06.036
BibTeX
@article{Rauf2026,
author = {Rauf, Muhammad Umaid and Riefolo, Mattia and Wong, Ethan and Gilbertson, Janet and Petrie, Aviva and Law, Steven and Razvi, Yousuf and Mansell, Josephine and Sheikh, Awais and Carruthers, Jack and Ioannou, Adam and Porcari, Aldostefano and Hutt, David and Rowczenio, Dorota and Wurie, Hawah and Ravichandran, Sriram and Cohen, Oliver C and Khawaja, Jahanzaib and Bomsztyk, Joshua and Rezk, Tamer and Martinez-Naharro, Ana and Whelan, Carol and Lachmann, Helen J and Wechalekar, Ashutosh D and Hawkins, Philip N and Fontana, Marianna and Gillmore, Julian D},
title = {Evaluation of CD68+ macrophages in relation to kidney outcomes in immunoglobulin light-chain amyloidosis},
journal = {Kidney International},
year = {2026},
doi = {10.1016/j.kint.2026.06.036}
}
EUVIMED